News und Analysen

LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval^® Plus sutureless surgical aortic heart valve is now available for

Virginia Mason Health System, a leading non-profit regional healthcare system serving the Pacific Northwest, and Premier Inc. (NASDAQ: PINC), a healthcare improvement company, have partnered to

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating

Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5^th, before the market opens. A conference call has been scheduled

Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan^® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize

Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, following the close of trading on the

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)

Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials¹, which details the design for “A Prospective

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management

Nearly 90 percent of healthcare providers are contributing to stockpiles of critical medical supplies and drugs intended to last as long as 90 days, according to a recent survey conducted by

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab bekannt, dass die Aktionäre heute auf der Jahreshauptversammlung des Unternehmens allen Beschlussvorschlägen im Zusammenhang mit dem

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that the majority of alternate site providers, including senior living facilities

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it plans to provide in the first half of July 2020 an overview of preliminary results for the second quarter and first

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Pläne bekannt, in der ersten Julihälfte 2020 einen Überblick über vorläufige Ergebnisse für das zweite Quartal und die erste Hälfte

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty

Recordati Rare Diseases meldet heute positive Ergebnisse der großen Phase-III-Studie LINC-4 zur Prüfung von Isturisa^® (Osilodrostat) zur Behandlung von Patienten mit Morbus Cushing, die für eine

Recordati Rare Diseases today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S